Skip to content

LIMN

Liminatus Pharma, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.48
+2.65%
Ask drillr
Institutional positioning

13F filings over the trailing two quarters

New 10Increased 6Reduced 9Sold out 5
FilerActionSharesFiled
CITADEL ADVISORS LLCIncreased677,518May 15, 2026
Cygnus Capital Advisors, LLCNew Position350,000May 13, 2026
Cygnus Capital Advisors, LLCReduced329,333Sep 3, 2026
XTX Topco LtdNew Position221,839Aug 14, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased138,418Aug 12, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased117,783May 15, 2026
JANE STREET GROUP, LLCNew Position71,318May 12, 2026
CITADEL ADVISORS LLCReduced56,089Sep 2, 2026
UBS GROUP AGIncreased54,578May 5, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position50,440May 15, 2026
VANGUARD CAPITAL MANAGEMENT LLCUnchanged50,440Aug 13, 2026
GOLDMAN SACHS GROUP INCNew Position40,220Aug 14, 2026
VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLCNew Position34,706May 14, 2026
VIRTU FINANCIAL LLCNew Position27,468May 14, 2026
StoneX Group Inc.New Position26,058Aug 12, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings